Biotech’s week traded distress for discipline: Sangamo’s bankruptcy auction let PTC Therapeutics pick up a near-approval Fabry gene therapy for a fraction of its original value, Bristol Myers Squibb banked the first-ever approval of…
The FDA granted accelerated approval to Bristol Myers Squibb’s iberdomide (Zenbexus), the company’s first approved CELMoD, in combination with daratumumab and hyaluronidase-fihj and dexamethasone, for multiple myeloma patients who have received at least one…
The European Medicines Agency published its scientific reasoning for revoking the European marketing authorization of Amgen’s avacopan (Tavneos), citing serious breaches of clinical trial conduct in the drug’s pivotal study—including unblinded access to efficacy…
Silence Therapeutics priced an underwritten public offering of American Depositary Shares expected to generate approximately $175 million in gross proceeds, upsized from an initially announced $150 million target, one day after reporting positive Phase…
PTC Therapeutics has agreed to pay $111 million upfront, plus up to $100 million in regulatory milestones, to acquire ST-920 (isaralgagene civaparvovec), a BLA-stage one-time AAV gene therapy for Fabry disease, from bankrupt Sangamo…
Zealand Pharma sold its legacy economic interests in rusfertide, Takeda’s investigational hepcidin-mimetic therapy for polycythemia vera, to Royalty Pharma for $100 million—$50 million upfront and $50 million on the first anniversary of closing. Zealand…
The FDA approved Moderna’s mFLUSIVA (mRNA-1010), the first mRNA-based seasonal influenza vaccine authorized in the United States, for adults age 50 and older. The approval is split into two tiers: full approval for adults…
Attovia Therapeutics priced an upsized initial public offering of 17 million shares at $17 per share, the top of its marketed range, for expected gross proceeds of $289 million before underwriting discounts and expenses….
Damora Therapeutics initiated CLARITY-101, a global Phase 1/1b trial of DMR-001 in adults with mutant-calreticulin-driven essential thrombocythemia or myelofibrosis. DMR-001 is an Fc-null monoclonal antibody designed to bind Type 1 and non-Type 1 mutant…
Expedition Therapeutics closed an oversubscribed $115 million Series B led by General Atlantic, with RA Capital, Vivo Capital and all existing investors participating. The company simultaneously disclosed first-patient dosing in its global Phase 2…
